Livzon's IL-17 Inhibitor Lecankitug Nears Second Indication as NMPA Accepts Ankylosing Spondylitis Application
Key Insights
Livzon MABPharm (search)'s marketing authorization application for Lecankitug (search) Injection has been accepted for review by China's NMPA for active ankylosing spondylitis (search).
The pivotal Phase III trial demonstrated rapid onset, strong and sustained efficacy up to 52 weeks, with a safety profile comparable to placebo.
Lecankitug (search) is a domestically developed Class 1 therapeutic biological product targeting IL-17 (search), offering convenient four-week subcutaneous dosing.
Livzon MABPharm (search), a subsidiary of Livzon Pharmaceutical Group (search), has reached a significant regulatory milestone as China's National Medical Products Administration (NMPA) formally accepted its marketing authorization application for Lecankitug (search) Injection for the treatment of adult patients with active ankylosing spondylitis (search) who have not responded adequately to conventional therapy.
The domestically developed Class 1 therapeutic biological product represents a growing focus on IL-17 (search)-targeted therapies in China's biopharmaceutical landscape. Lecankitug (search) is designed to address a substantial patient population — an estimated 4 million individuals living with ankylosing spondylitis (search) across China.
Pivotal Phase III Evidence Supports Filing
The application is backed by a pivotal Phase III multicenter, randomized, double-blind, placebo-controlled trial. According to the company, the study demonstrated rapid onset of action, strong and sustained efficacy lasting up to 52 weeks, and a safety profile comparable to placebo. These findings position Lecankitug (search) as a potentially meaningful addition to the treatment armamentarium for patients who have exhausted conventional therapeutic options.
The drug's dosing regimen — a convenient four-week subcutaneous injection — may offer practical advantages in real-world clinical settings, potentially improving treatment adherence among patients requiring long-term immunomodulatory therapy.
Expanding the IL-17 (search) Franchise
If approved, Lecankitug (search) would secure its second indication following the earlier psoriasis application, further strengthening Livzon's footprint in the IL-17 (search) inhibitor space. The IL-17 pathway has emerged as a validated target in multiple autoimmune and inflammatory conditions, with several approved therapies already demonstrating clinical benefit across indications including plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
The acceptance of the application by the NMPA marks a critical step toward potentially broadening treatment options for ankylosing spondylitis (search) patients in China, where access to biologic therapies continues to expand amid growing recognition of the disease burden associated with chronic inflammatory conditions.